Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.06.27.661912

Multiple sclerosis-associated HLA demarcates EBV-specific CD8+ T cells with an exhausted and brain residency phenotype

Abstract

Specific HLA class I subtypes as well as circulating antibodies against Epstein-Barr virus (EBV) have been associated with increased susceptibility to develop multiple sclerosis (MS). It is currently unclear whether and how these risk factors are functionally related. Here, we assessed the impact of MS risk allele HLA-B7 and protective allele HLA-A2 on the effector phenotype of EBV-specific CD8+ T cells and if this corresponds with anti-EBV IgG titers. For this, we selected HLA-A2+ and/or HLA-B7+ donors with and without MS and analyzed HLA-restricted, EBV- specific CD8+ T cells with different fine-specificities using 38 color-based spectral flow cytometry. In contrast to HLA-A2-restricted CD8+ T cells, HLA-B7-restricted CD8+ T cells showed a confined response to EBV, which was mainly directed against latent peptide EBNA3A(379-387). These HLA-B7-restricted EBV-specific CD8+ T cells expressed higher levels of CNS residency markers CXCR3 and CD20 and were most abundant in fresh single-cell suspensions derived from different post-mortem CNS compartments of an HLA-A2+B7+ MS donor. Moreover, HLA-B7- restricted EBV-specific CD8+ T cells displayed a more exhausted phenotype (PD- 1+CD244+CD160+KLRG1+TIGIT+) that stood out in the blood from people with MS (pwMS). Accordingly, in the blood, increased IgG titers against EBV were found for pwMS carrying HLA- B7 but lacking HLA-A2, which seemed to coincide with HLA-B7-restricted EBV-specific CD8+ T cells having such an effector phenotype. These data support a model in which the confined response against EBV makes circulating HLA-B7-restricted CD8+ T cells less able to control EBV and more prone to infiltrate the CNS in pwMS.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Reijm, S., Marques, A. M., Rip, J., Corsten, C. E. A., Wierenga-Wolf, A. F., de Wit, H., Melief, M.-J., van Hasselt, Y., van Langelaar, J., Neuteboom, R., Wokke, B. H. A., Mueller, Y. M., Smolders, J., van Luijn, M. M.. 2025-07-02. Multiple sclerosis-associated HLA demarcates EBV-specific CD8+ T cells with an exhausted and brain residency phenotype. https://doi.org/10.1101/2025.06.27.661912

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗